Search results for "Verteporfin"

showing 10 items of 12 documents

Back pain after photodynamic therapy with verteporfin.

2005

Purpose To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. Design Retrospective case series. Methods We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. Results Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group ( P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patient…

Malemedicine.medical_specialtyPorphyrinsmedicine.medical_treatmentPhotodynamic therapyMacular Degenerationback painphotodynamic therapymedicineBack painHumansInfusions IntravenousAgedRetrospective StudiesAged 80 and overPhotosensitizing AgentsMild painSettore MED/30 - Malattie Apparato Visivobusiness.industryIncidence (epidemiology)IncidenceVerteporfinRetrospective cohort studyMacular degenerationMiddle Agedmedicine.diseaseVerteporfinLow back painChoroidal NeovascularizationSurgeryOphthalmologyPhotochemotherapyBack PainMyopia DegenerativeFemalemedicine.symptombusinessmedicine.drugAmerican journal of ophthalmology
researchProduct

Laserfotokoagulation und photodynamische Therapie (PDT) zur Behandlung der retinalen angiomatösen Proliferation (RAP) bei feuchter altersabhängiger M…

2008

BACKGROUND: Retinal angiomatous proliferation (RAP) is a subtype of neovascular age-related macular degeneration (AMD) with particularly bad prognosis. Diverse treatment modalities are performed. PATIENTS AND METHODS: This is a retrospective review on the treatment results of 41 consecutive patients from 1 / 2003 to 12 / 2005 with RAP stage 1 - 3 (Yannuzzi classification), who were treated with laser photocoagulation, photodynamic therapy (PDT) and intravitreal injection of triamcinolone acetonide (IVT). Follow-up was 12 months minimally. RESULTS: In RAP stage I complete closure of the vascular lesion in 14 / 22 eyes was achieved by 1.2 ± 0.5 sessions of laser photocoagulation (4 × combined…

medicine.medical_specialtyVisual acuityTriamcinolone acetonideRetinal pigment epitheliumgenetic structuresbusiness.industryRetinalMacular degenerationmedicine.diseaseVerteporfineye diseasesSurgeryLesionOphthalmologychemistry.chemical_compoundmedicine.anatomical_structurechemistryOphthalmologymedicineTearssense organsmedicine.symptombusinessmedicine.drugKlinische Monatsblätter für Augenheilkunde
researchProduct

Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of …

2018

PurposeTo compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT).MethodsThis is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m2) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm.ResultsIn the MP group, at 12 months of follow-up, the mean best corr…

Laser surgeryMaleFluorescein angiographyretinaVisual acuityoptical coherencegenetic structuresPhysiologymedicine.medical_treatmentCentral serous chorioretinopathyVisual AcuityPhotodynamic therapytreatment lasersProceduresPhotodynamic therapychemistry.chemical_compound0302 clinical medicineBest corrected visual acuityMedicineFluorescein AngiographyTreatment outcomeMiddle agedTomographyPriority journalLow level laser therapyPhotosensitizing Agentsmedicine.diagnostic_testMiddle AgedFluorescein angiographyVerteporfinPhotosensitizing agentsSensory SystemsIndocyanine greenMulticenter studyBevacizumabClinical trialRetrospective studyTreatment OutcomeCentral Serous ChorioretinopathyFemaleLaser Therapymedicine.symptomTomography Optical Coherencemedicine.drugHumanIndocyanine GreenAdultmedicine.medical_specialtyVisual acuityLaser surgeryMajor clinical studyFollow-up studiesPathophysiologyArticleChronic disease03 medical and health sciencesCellular and Molecular NeuroscienceLaser therapyOphthalmologyFluorescence angiographyHumansmaculaLow level laser therapyRetrospective StudiesDisease durationPhotosensitizing agentOptical coherence tomographybusiness.industryIntermethod comparisonSubretinal neovascularizationCentral serous retinopathyVerteporfinFollow upmedicine.diseaseMulticenter study (topic)eye diseasesRetrospective studiesOphthalmologyCentral serous retinopathychemistryPhotochemotherapyChronic Disease030221 ophthalmology & optometryYellow micropulse laserComparative studysense organsbusinessIndocyanine greenControlled study030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Clinical Outcome and Subjective Quality of Life after Photodynamic Therapy in Patients with Age-Related Macular Degeneration

2005

PURPOSE. Whereas the efficacy of photodynamic therapy (PDT) in preventing the progression of age-related macular degeneration (ARMD) is established, its effect on quality of life is under discussion. METHODS. All patientswho underwent PDT during 2000 and 2001 at the University Eye Hospital of Mainz were interviewed using a standardized 82-item questionnaire on quality of life and patient satisfaction in ophthalmologic patients. Information was assessed in terms of 82 questions; global scores ranging from 1.0 (optimum self-estimated quality of life) to 4.0 (worst) were derived. Cataract patients' scores were used to characterize the ARMD patients' subjective outcome; the latter were then rel…

Malemedicine.medical_specialtyPorphyrinsVisual acuitymedicine.medical_treatmentVisual AcuityPsychological interventionPhotodynamic therapyLogistic regressionMacular Degeneration03 medical and health sciences0302 clinical medicinePatient satisfactionQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineHumansIn patientAgedRetrospective StudiesAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMacular degenerationmedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyCross-Sectional StudiesTreatment OutcomePhotochemotherapyPatient SatisfactionQuality of Life030221 ophthalmology & optometryPhysical therapyFemalemedicine.symptombusiness030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct

PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR D…

2007

Abstract PURPOSE: To assess the effectiveness of photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV) associated with retinal pigment epithelium detachment (PED) in age-related macular degeneration. METHODS: Thirty eyes of 26 patients with CNV and PED were treated with PDT. The eyes were divided in two groups based on CNV location in relation to PED; group 1 included 13 eyes with CNV within PED, and group 2 included 17 eyes with CNV at the edge of PED. The median follow-up was 16 months. RESULTS: Patients received a mean +/- SD of 2.83 +/- 1.26 treatments (range, 1-6 treatments). In the whole cohort, the mean preoperative visual acuity changed from 20/144 (0.86…

Malemedicine.medical_specialtyPorphyrinsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyMacular DegenerationAge relatedOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyPigment Epithelium of EyeAgedAged 80 and overPhotosensitizing AgentsRetinal pigment epitheliumSettore MED/30 - Malattie Apparato Visivobusiness.industryRetinal DetachmentVerteporfinGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyFemaleRetinal pigment epithelial detachmentsense organsPhotodynamic therapy choroidal neovascularization age-related macular degenerationmedicine.symptombusinessFollow-Up Studiesmedicine.drugRetina
researchProduct

Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer

2016

Background & Aims Many different types of cancer cells have chromosome instability. The hippo pathway leads to phosphorylation of the transcriptional activator yes-associated protein 1 (YAP1, YAP), which regulates proliferation and has been associated with the development of liver cancer. We investigated the effects of hippo signaling via YAP on chromosome stability and hepatocarcinogenesis in humans and mice. Methods We analyzed transcriptome data from 242 patients with hepatocellular carcinoma (HCC) to search for gene signatures associated with chromosomal instability (CIN); we investigated associations with overall survival time and cancer recurrence using Kaplan–Meier curves. We analyze…

0301 basic medicineTime FactorsMuscle ProteinsKaplan-Meier Estimatemedicine.disease_causeChromosome instabilityYAP1Liver NeoplasmsGastroenterologyTEA Domain Transcription FactorsHep G2 CellsPrognosisDNA-Binding ProteinsGene Expression Regulation NeoplasticPhenotypeHippo signalingRNA InterferenceSignal TransductionCarcinoma HepatocellularPorphyrinsAntineoplastic AgentsMice TransgenicBiologyTransfection03 medical and health sciencesChromosomal InstabilitymedicineAnimalsHumansGene silencingGenetic Predisposition to DiseaseAdaptor Proteins Signal TransducingHippo signaling pathwayHepatologyGene Expression ProfilingForkhead Box Protein M1VerteporfinYAP-Signaling ProteinsHCCSPhosphoproteinsThiostreptonMolecular biologyMice Inbred C57BLDisease Models Animal030104 developmental biologyTissue Array AnalysisFOXM1Cancer researchTranscriptomeCarcinogenesisTranscription FactorsGastroenterology
researchProduct

Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study.

2007

Purpose To assess the effect of verteporfin photodynamic therapy (PDT) in juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Design Prospective, open-label, consecutive, interventional case series. Methods We prospectively followed a series of 48 consecutive patients (49 eyes) with pathologic myopia (≥ 6 diopters) who received verteporfin PDT for juxtafoveal CNV. This population was divided into two groups based on age (group A ≤ 55 years old, group B >55 years old), in three subgroups based on CNV lesion size, and in three categories based on refractive error at baseline. Results The median follow-up was 32 months (range, 12 to 56 months). Visual acuity (VA…

AdultMalemedicine.medical_specialtyRefractive errorFovea CentralisVisual acuityPorphyrinsgenetic structuresEye diseasePopulationVisual AcuityVision disorderlavoro clinico con dati originaliOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyeducationDioptreAgedAged 80 and overeducation.field_of_studyPhotosensitizing Agentsbusiness.industryVerteporfinMiddle Agedmedicine.diseasePrognosisVerteporfineye diseasesChoroidal NeovascularizationOphthalmologyChoroidal neovascularizationPhotochemotherapyMyopia DegenerativeFemalesense organsmedicine.symptombusinessmedicine.drugFollow-Up StudiesAmerican journal of ophthalmology
researchProduct

Evolving European guidance on the medical management of neovascular age related macular degeneration

2006

BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. METHODS: Consensus from a round table of European retina specialists was obt…

medicine.medical_specialtygenetic structuresBevacizumabAntibodies Monoclonal HumanizedTriamcinolone AcetonideMacular DegenerationCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansPregnadienediolsEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryAntibodies MonoclonalAptamers NucleotideMacular degenerationFluorescein angiographymedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesSensory SystemsOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyPerspectivesense organsAnecortave acetateChoroidRanibizumabmedicine.symptombusinessmedicine.drugBritish Journal of Ophthalmology
researchProduct

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.

2006

Purpose: To assess the safety and effectiveness of photodynamic therapy (PDT) with verteporfin for subfoveal choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Methods: Sixty-two patients (62 eyes) with PM underwent PDT according to the guidelines of the Verteporfin in Photodynamic Therapy Study. Clinical evaluations performed at all study visits included measurement of best-corrected Snellen visual acuity, slit-lamp biomicroscopy, and fundus fluorescein angiography. Patients were followed up at 1 month and 3 months after treatment and thereafter at 3-month intervals. Results: The final visual acuity of the study patients, after a median follow-up of 31 months, improved…

AdultMaleRefractive errormedicine.medical_specialtyFovea CentralisVisual acuityPorphyrinsgenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyOphthalmologyPathologic myopiamedicineHumansProspective StudiesFluorescein AngiographyDioptreAgedAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMiddle Agedmedicine.diseaseVerteporfineye diseasesChoroidal NeovascularizationOphthalmologyLong term learningChoroidal neovascularizationPhotochemotherapyMyopia DegenerativeFemalesense organsmedicine.symptombusinessmyopia subfoveal choroidal neovascularization photodynamic therapy verteporfin.medicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct

In vivo efficacy of verteporfin loaded gold nanorods for combined photothermal/photodynamic colon cancer therapy.

2022

The high incidence of cancer recurrences and the frequent occurrence of multidrug resistance often stem from a poorly selective and inefficient antineoplastic therapy, responsible for the onset of undesired side effects as well. A combination of minimal-invasive approaches could thus be a useful strategy to surmount these shortcomings, achieving a safe and solid cancer therapy. Herein, a multi-therapeutic nanotool was designed by merging the photothermal properties of gold nanorods (AuNRs) with the photodynamic activity of the photosensitizer ver-teporfin. AuNRs were coated with the natural materials lipoic acid and gellan gum (AuNRs_LA,GG) and subse-quently loaded with verteporfin (AuNRs_L…

NanotubesHuman colon cancerPharmaceutical ScienceVerteporfinHyperthermia InducedPhototherapyGold nanorodsPhotothermal therapyGellan gumPhotodynamic therapyMiceCell Line TumorColonic NeoplasmsAnimalsHumansGoldInternational journal of pharmaceutics
researchProduct